Table 2 Results relating to clinical change and study attrition.
Months | Number of trials | Chlorpromazine | Placebo | RR (95% CI) | Test for heterogeneity | |
|---|---|---|---|---|---|---|
events/total participants | ||||||
Relapse | 6–24 | 3 | 108/202 | 159/192 | 0.65 (0.5–9.0) | Chi2 7.83, df 2, p = 0.02 I2 = 74.5%* |
No global improvement | 2–6 | 13 | 470/654 | 406/467 | 0.76 (0.7–0.9) | Chi2 25.4, df 12, p = 0.01 I2 = 52.8% |
Leaving the study early | 6–24 | 2 | 38/254 | 33/238 | 1.09 (0.7–1.6) | Chi2 0.47, df 1, p = 0.49 I2 = 0% |